BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26881937)

  • 1. Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells.
    Lin X; Liao Y; Chen X; Long D; Yu T; Shen F
    Cancer Biother Radiopharm; 2016 Mar; 31(2):37-43. PubMed ID: 26881937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro.
    Chen X; Liao Y; Long D; Yu T; Shen F; Lin X
    Int J Mol Med; 2017 Jul; 40(1):235-242. PubMed ID: 28534969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.
    Lin X; Liao Y; Xie J; Liu S; Su L; Zou H
    Cancer Biother Radiopharm; 2014 Nov; 29(9):376-86. PubMed ID: 25379611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinblastine differs from Taxol as it inhibits the malignant phenotypes of NSCLC cells by increasing the phosphorylation of Op18/stathmin.
    Shen F; Long D; Yu T; Chen X; Liao Y; Wu Y; Lin X
    Oncol Rep; 2017 Apr; 37(4):2481-2489. PubMed ID: 28259950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice.
    Lin X; Yu T; Zhang L; Chen S; Chen X; Liao Y; Long D; Shen F
    Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):611-620. PubMed ID: 27289016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction of exogenous wild‑type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor‑κB in non‑small cell lung cancer NCI‑H1299 cells.
    Chen S; Zhao Y; Shen F; Long D; Yu T; Lin X
    Oncol Rep; 2019 Mar; 41(3):2051-2059. PubMed ID: 30628717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNAi targeting STMN alleviates the resistance to taxol and collectively contributes to down regulate the malignancy of NSCLC cells in vitro and in vivo.
    Long D; Yu T; Chen X; Liao Y; Lin X
    Cell Biol Toxicol; 2018 Feb; 34(1):7-21. PubMed ID: 28589243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro neutralization of autocrine IL‑10 affects Op18/stathmin signaling in non‑small cell lung cancer cells.
    Zhao Y; Chen S; Shen F; Long D; Yu T; Wu M; Lin X
    Oncol Rep; 2019 Jan; 41(1):501-511. PubMed ID: 30320402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.
    Han ZX; Wang HM; Jiang G; Du XP; Gao XY; Pei DS
    Cancer Biother Radiopharm; 2013 Jun; 28(5):398-405. PubMed ID: 23496232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of RhoGDIα induces apoptosis and increases lung cancer cell chemosensitivity to paclitaxel.
    Rong F; Li W; Chen K; Li DM; Duan WM; Feng YZ; Li F; Zhou XW; Fan SJ; Liu Y; Tao M
    Neoplasma; 2012; 59(5):541-50. PubMed ID: 22668020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus-encoded LMP1 triggers regulation of the ERK-mediated Op18/stathmin signaling pathway in association with cell cycle.
    Lin X; Tang M; Tao Y; Li L; Liu S; Guo L; Li Z; Ma X; Xu J; Cao Y
    Cancer Sci; 2012 Jun; 103(6):993-9. PubMed ID: 22417000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells.
    Suyama H; Igishi T; Sano H; Matsumoto S; Shigeoka Y; Nakanishi H; Endo M; Burioka N; Hitsuda Y; Shimizu E
    Int J Oncol; 2004 Jun; 24(6):1499-504. PubMed ID: 15138593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
    Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
    Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin.
    Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F
    Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells.
    Nishio K; Nakamura T; Koh Y; Kanzawa F; Tamura T; Saijo N
    Cancer; 2001 Apr; 91(8):1494-9. PubMed ID: 11301397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Op18/stathmin as a potential target of ASK1-p38 MAP kinase cascade.
    Mizumura K; Takeda K; Hashimoto S; Horie T; Ichijo H
    J Cell Physiol; 2006 Feb; 206(2):363-70. PubMed ID: 16110469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.
    Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z
    Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
    Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
    PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.